Crooke S T, Comis R L, Einhorn L H, Strong J E, Broughton A, Prestayko A W
Cancer Treat Rep. 1977 Dec;61(9):1631-6.
The clinical pharmacology of bleomycin administered as an iv bolus has been studied in a homogeneous group of patients receiving a single regimen containing bleomycin, vinblastine, and cis-dichlorodiammineplatinum (II). These studies demonstrated that in patients with creatinine clearances greater than or equal to 35 ml/minute, the serum (or plasma) terminal elimination half-life of bleomycin was approximately 115 minutes. In patients with creatinine clearances less than 25-35 ml/minute, the terminal elimination half-life increased exponentially as the creatinine clearance decreased. The volume of distribution was approximately 20 liters, and was unaffected by changes in the creatinine clearance. The microbiologic assay and radioimmunoassay employed gave equivalent results.
对接受包含博来霉素、长春碱和顺二氯二氨铂（II）单一治疗方案的一组同质患者，研究了静脉推注博来霉素的临床药理学。这些研究表明，肌酐清除率大于或等于35毫升/分钟的患者，博来霉素的血清（或血浆）终末消除半衰期约为115分钟。肌酐清除率低于25 - 35毫升/分钟的患者，随着肌酐清除率降低，终末消除半衰期呈指数增加。分布容积约为20升，不受肌酐清除率变化的影响。所采用的微生物学测定和放射免疫测定给出了等效结果。
